Fundamental Analysis of ITERUM THERAPEUTICS PLC(NASDAQ:ITRM) stock

Fundamental Rating

ITRM gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. ITRM has a bad profitability rating. Also its financial health evaluation is rather negative. ITRM has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ITRM had negative earnings in the past year.

ITRM had a negative operating cash flow in the past year.

In the past 5 years ITRM always reported negative net income.

In the past 5 years ITRM always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -191.87%, ITRM is not doing good in the industry: 88.59% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-191.87%
ROE	N/A
ROIC	N/A

ROA(3y)-104.22%

ROA(5y)-174.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ITRM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ITRM has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ITRM has been increased compared to 5 years ago.

The debt/assets ratio for ITRM is higher compared to a year ago.

2.2 Solvency

ITRM has an Altman-Z score of -46.71. This is a bad value and indicates that ITRM is not financially healthy and even has some risk of bankruptcy.

ITRM has a Altman-Z score of -46.71. This is amonst the worse of the industry: ITRM underperforms 92.93% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-46.71

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ITRM has a Current Ratio of 0.85. This is a bad value and indicates that ITRM is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of ITRM (0.85) is worse than 91.30% of its industry peers.

ITRM has a Quick Ratio of 0.85. This is a bad value and indicates that ITRM is not financially healthy enough and could expect problems in meeting its short term obligations.

ITRM has a Quick ratio of 0.85. This is amonst the worse of the industry: ITRM underperforms 84.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.85
Quick Ratio	0.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.88% over the past year.

EPS 1Y (TTM)17.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ITRM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.71% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y60.41%

EPS Next 2Y32.4%

EPS Next 3Y21.77%

EPS Next 5Y15.71%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ITRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ITRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ITRM's earnings are expected to grow with 21.77% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.4%

EPS Next 3Y21.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ITRM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ITERUM THERAPEUTICS PLC

NASDAQ:ITRM (1/3/2025, 8:00:02 PM)

After market: 1.95 +0.05 (+2.63%)

1.9

+0.07 (+3.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-14 2024-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners3.05%

Inst Owner Change0%

Ins Owners1.81%

Ins Owner Change0%

Market Cap52.29M

Analysts82.5

Price Target7.65 (302.63%)

Short Float %8.34%

Short Ratio0.62

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-6.21%

Min EPS beat(2)-47.06%

Max EPS beat(2)34.64%

EPS beat(4)3

Avg EPS beat(4)6.7%

Min EPS beat(4)-47.06%

Max EPS beat(4)37.8%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)25%

EPS NQ rev (1m)0%

EPS NQ rev (3m)48.65%

EPS NY rev (1m)-11.43%

EPS NY rev (3m)-5.41%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2

EYN/A

EPS(NY)-0.74

Fwd EYN/A

FCF(TTM)-1.28

FCFYN/A

OCF(TTM)-1.28

OCFYN/A

SpS0

BVpS-0.42

TBVpS-0.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-191.87%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-104.22%

ROA(5y)-174.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1.08%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.85
Quick Ratio	0.85
Altman-Z	-46.71

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)2.31%

Cap/Depr(5y)5.3%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)17.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y60.41%

EPS Next 2Y32.4%

EPS Next 3Y21.77%

EPS Next 5Y15.71%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y39.83%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-111.73%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-112.08%

OCF growth 3YN/A

OCF growth 5YN/A

ITERUM THERAPEUTICS PLC (ITRM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens